JW Pharmaceutical Corporation

KOSE:A001060 Stock Report

Market Cap: ₩591.4b

JW Pharmaceutical Valuation

Is A001060 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A001060 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A001060 (₩23650) is trading below our estimate of fair value (₩92166.57)

Significantly Below Fair Value: A001060 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A001060?

Key metric: As A001060 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A001060. This is calculated by dividing A001060's market cap by their current earnings.
What is A001060's PE Ratio?
PE Ratio8x
Earnings₩72.89b
Market Cap₩591.39b

Price to Earnings Ratio vs Peers

How does A001060's PE Ratio compare to its peers?

The above table shows the PE ratio for A001060 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average10.4x
A000640 Dong-A Socio Holdings
11.8xn/a₩650.7b
A086450 DongKook Pharmaceutical
12x11.9%₩751.4b
A003850 Boryung
10.7x12.1%₩678.4b
A003090 Daewoong
7xn/a₩838.3b
A001060 JW Pharmaceutical
8x13.3%₩591.4b

Price-To-Earnings vs Peers: A001060 is good value based on its Price-To-Earnings Ratio (8x) compared to the peer average (10.4x).

Price to Earnings Ratio vs Industry

How does A001060's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A007370 Jin Yang Pharmaceutical
2.4xn/aUS$48.35m
No more companies available in this PE range
A001060 8.0xIndustry Avg. 11.4xNo. of Companies10PE01020304050+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A001060 is good value based on its Price-To-Earnings Ratio (8x) compared to the KR Pharmaceuticals industry average (11.4x).

Price to Earnings Ratio vs Fair Ratio

What is A001060's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A001060 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8x
Fair PE Ratio17.6x

Price-To-Earnings vs Fair Ratio: A001060 is good value based on its Price-To-Earnings Ratio (8x) compared to the estimated Fair Price-To-Earnings Ratio (17.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A001060 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩23,550.00
₩41,500.00
+76.2%
8.4%₩45,000.00₩38,000.00n/a2
Nov ’25₩27,000.00
₩41,500.00
+53.7%
8.4%₩45,000.00₩38,000.00n/a2
Oct ’25₩27,550.00
₩41,500.00
+50.6%
8.4%₩45,000.00₩38,000.00n/a2
Sep ’25₩29,650.00
₩41,500.00
+40.0%
8.4%₩45,000.00₩38,000.00n/a2
Aug ’25₩31,850.00
₩41,666.67
+30.8%
6.9%₩45,000.00₩38,000.00n/a3
Jul ’25₩30,050.00
₩41,666.67
+38.7%
6.9%₩45,000.00₩38,000.00n/a3
Jun ’25₩28,700.00
₩41,666.67
+45.2%
6.9%₩45,000.00₩38,000.00n/a3
May ’25₩30,950.00
₩41,666.67
+34.6%
6.9%₩45,000.00₩38,000.00n/a3
Apr ’25₩33,250.00
₩41,666.67
+25.3%
6.9%₩45,000.00₩38,000.00n/a3
Mar ’25₩32,900.00
₩41,666.67
+26.6%
6.9%₩45,000.00₩38,000.00n/a3
Feb ’25₩30,400.00
₩40,808.82
+34.2%
7.1%₩45,000.00₩38,000.00n/a4
Jan ’25₩35,550.00
₩36,274.51
+2.0%
5.8%₩38,235.29₩33,333.33n/a3
Dec ’24₩29,411.76
₩36,274.51
+23.3%
5.8%₩38,235.29₩33,333.33n/a3
Nov ’24₩25,490.20
₩36,274.51
+42.3%
5.8%₩38,235.29₩33,333.33₩27,000.003
Oct ’24₩37,549.02
₩36,274.51
-3.4%
5.8%₩38,235.29₩33,333.33₩27,550.003
Sep ’24₩42,794.12
₩36,274.51
-15.2%
5.8%₩38,235.29₩33,333.33₩29,650.003
Aug ’24₩34,068.63
₩35,534.46
+4.3%
6.3%₩38,235.29₩33,314.30₩31,850.004
Jul ’24₩22,745.10
₩32,833.62
+44.4%
1.5%₩33,314.30₩32,352.94₩30,050.002
Jun ’24₩23,186.27
₩32,833.62
+41.6%
1.5%₩33,314.30₩32,352.94₩28,700.002
May ’24₩22,254.90
₩31,363.03
+40.9%
6.2%₩33,314.30₩29,411.76₩30,950.002
Apr ’24₩20,343.14
₩30,934.70
+52.1%
7.7%₩33,314.30₩28,555.11₩33,250.002
Mar ’24₩19,798.21
₩30,934.70
+56.3%
7.7%₩33,314.30₩28,555.11₩32,900.002
Feb ’24₩19,274.70
₩30,934.70
+60.5%
7.7%₩33,314.30₩28,555.11₩30,400.002
Jan ’24₩17,989.72
₩30,934.70
+72.0%
7.7%₩33,314.30₩28,555.11₩35,550.002
Dec ’23₩18,893.97
₩31,410.62
+66.2%
6.5%₩33,314.30₩28,555.11₩29,411.763
Nov ’23₩18,132.50
₩31,410.62
+73.2%
6.5%₩33,314.30₩28,555.11₩25,490.203

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Hugel

₩2.8t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩272,000.00

7D

-3.5%

1Y

79.4%

J2KBIO

₩54.3b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,540.00

7D

3.6%

1Y

n/a

Ildong Pharmaceutical

₩340.2b

Develops, manufactures, and sells pharmaceutical products in South Korea.

A249420

₩12,130.00

7D

-2.0%

1Y

-27.6%